The Obesity Shot That Wants You to Forget About It

Obesity drugs only work if people keep taking them. And in the real world, long-term persistence is a major bottleneck. Cost, access, and the sheer inconvenience of weekly injections all chip away at adherence over time. Anything that reduces the treatment burden could meaningfully expand how many patients stick with therapy.

That's Viking's angle. Monthly maintenance dosing is a convenience play, and in a chronic disease that requires lifelong treatment, convenience isn't a luxury; it's a strategy.

What VK2735 Actually Is

VK2735 is a dual GLP-1/GIP receptor agonist, which is a mouthful that means it activates two hormonal pathways involved in appetite and metabolism. GLP-1 (the same pathway behind Wegovy and Ozempic) suppresses appetite, slows digestion, and helps regulate blood sugar. GIP adds complementary metabolic effects that may boost efficacy and tolerability.

If this sounds familiar, it should. Eli Lilly's Zepbound also targets both GLP-1 and GIP receptors. Viking's twist is the molecule's extended half-life, which is what makes less frequent dosing possible in the first place. The drug sticks around in the body longer, maintaining its effect even when you space out the shots.

During the weekly induction phase, patients in one exploratory cohort achieved about 22% placebo-adjusted weight loss at week 33. Earlier Phase 2 data showed up to 14.7% weight loss after just 13 weekly doses with no plateau in sight. Those are competitive numbers, though the real Phase 3 test is still ahead.

The Scoreboard So Far

Viking has two Phase 3 trials (called VANQUISH-1 and VANQUISH-2) fully enrolled, with results expected in the second half of 2027. Both are large, 78-week studies testing weekly subcutaneous VK2735 against placebo. If those read out well, Viking will have the data it needs to file for FDA approval.

The company is also developing an oral version of VK2735, which showed up to 12.2% weight loss in a Phase 2 study after 13 weeks. And Viking has hinted at studying oral maintenance dosing too, which would mean patients could potentially switch from injections to pills after the initial weight-loss phase. That's a one-two punch of convenience that neither Novo Nordisk nor Eli Lilly currently offers.

Wall Street noticed. The stock rose on the maintenance data, and biotech outlets described the readout as a "trifecta" of strong initial weight loss, durable maintenance, and multiple dosing options.

The Catch (There's Always a Catch)

Before anyone gets too excited, some caveats. This was a relatively small, short maintenance study: 12 weeks of follow-up after a 21-week induction, not the kind of large, long-duration trial regulators require for approval. The headline "97%" figure came from a single dose cohort in the every-other-week group; the broader averages were more modest (around 85-90%).

Viking also doesn't have the commercial infrastructure, physician relationships, or real-world safety database that Novo Nordisk and Eli Lilly have spent years building. Wegovy and Zepbound are proven, prescribed, and available today. VK2735 is still experimental, and Phase 3 results are at least a year away.

So the competitive read is nuanced. Viking isn't trying to out-muscle the incumbents on raw weight loss (at least not yet). It's trying to outmaneuver them on dosing convenience, betting that patients and doctors will value fewer injections enough to consider a newer option.

The Bottom Line

The obesity drug race has mostly been about how much weight patients lose. Viking just introduced a new variable: how often they have to think about it.

If monthly maintenance dosing holds up in Phase 3, Viking could carve out a real niche in a market that's projected to keep growing for years. The data aren't definitive yet, but the signal is strong enough to make both investors and incumbents pay attention.

Once a month. Nearly all the weight loss retained. In a market built on weekly injections, that's not just a convenience upgrade. It's a potential paradigm shift.

The Pill That Could Replace the Needle in Breast Cancer Treatment

Genentech's oral pill giredestrant just posted Phase 3 results in the NEJM that could shake up breast cancer treatment. In patients whose cancers outsmarted standard therapy, it cut the risk of progression by up to 62%, and Roche already has an FDA application under review.